Core Viewpoint - The article discusses the significant investment by Zhong Shanshan in Jinbo Biological, a company specializing in recombinant collagen products, highlighting the potential for growth in the beauty and medical aesthetics industry [4][5][20]. Group 1: Investment Details - Jinbo Biological announced two transactions, including introducing Yangshengtang as a strategic investor and transferring shares from founder Yang Xia to Hangzhou Jiushi, totaling an investment of 3.4 billion yuan [4][7]. - The strategic investment from Yangshengtang will involve issuing up to 717.57 million shares, potentially raising 2 billion yuan, marking the largest cash increase in the history of the Beijing Stock Exchange [7]. - After the transactions, Zhong Shanshan will hold a 10.58% stake in Jinbo Biological, making him the second-largest shareholder after Yang Xia [10]. Group 2: Company Background - Jinbo Biological, founded by Yang Xia, focuses on recombinant human collagen products and has achieved a market value of 40 billion yuan [5][16]. - The company’s main products include various medical devices and functional skincare products based on type A recombinant human collagen [16]. - Jinbo Biological's core product, the injectable recombinant type III human collagen, has been widely adopted, with over 2 million applications across approximately 4,000 medical institutions [16]. Group 3: Market Dynamics - The medical aesthetics industry, particularly recombinant collagen, is experiencing rapid growth, with Jinbo Biological reporting a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92% [17]. - The gross profit margin for Jinbo Biological reached 92%, surpassing that of leading companies like Kweichow Moutai [17]. - The article notes that the beauty industry is characterized by high repeat purchase rates, making it a lucrative market for investors [22].